09:55 AM EST - Theratechnologies inc. : And TaiMed Biologics, Inc. today announced a 12-year collaboration agreement to market and distribute ibalizumab in the United States and in Canada. Ibalizumab is a novel CD4-directed HIV entry-inhibitor and is the first humanized monoclonal antibody in clinical trials for the treatment of HIV. Theratechnologies inc.
shares T.TH are trading down $0.03 at $1.29.
